TP53 and colorectal carcinoma: We evaluated the effect of regorafenib in combination with the pan-PKD inhibitor CRT0066101 on the growth of various human CRC cell lines (HCT116 p53+/+, HCT116 p53−/−, RKO, HT-29, SW48 and SW48-TP53 [R273H]).